Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing ...

Research analysts at William Blair issued their Q1 2026 earnings estimates for shares of argenx in a research note issued on ...

Equities researchers at William Blair issued their Q4 2026 earnings estimates for argenx in a report released on Monday, ...

Combomed Pharma is proud to announce the launch of Crystaderm™, an over-the-counter pharmaceutical product designed to effectively treat acne and impetigo. With its innovative formula, Crystaderm™ ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

The Work and Pensions Secretary has announced plans to tighten the eligibility criteria for Personal Independence Payment ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Combomed Pharma is proud to announce the launch of Crystadermtm, an over-the-counter pharmaceutical product designed to effectively treat acne and impetigo. With its innovative formula, Crystadermtm ...

Signs and symptoms are abnormalities that can indicate a potential medical condition. Whereas a symptom is subjective, that is, apparent only to the patient (for example back pain or fatigue), a ...